Research

Clinical Trials Funded by Drug and Device Companies

Registered clinical trials that drug and device companies funded in 2025, with the U.S. doctors named as investigators and the hospitals and sites where they run. Search by condition, drug, sponsor or trial number.

Condition, drug, sponsor or NCT number

Status Any statusRecruitingActive, not recruitingCompletedTerminated

Show

2,065 trials, most industry funding first

1. Phase 1/2 Clinical Trial of PR001 in Infants With Type 2 Gaucher Disease (PROVIDE)

   Active, not recruiting · Phase 1, Phase 2 · Gaucher Disease, Type 2

   NCT04411654 · Eli Lilly and Company · 3 U.S. investigators

   $274,759research payments

2. A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

   Active, not recruiting · Phase 3 · Idiopathic Pulmonary Fibrosis

   NCT06003426 · E.r. Squibb & Sons, L.l.c. · 23 U.S. investigators

   $274,406research payments

3. A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors

   Active, not recruiting · Phase 1, Phase 2 · Medullary Thyroid Cancer

   NCT03899792 · Eli Lilly and Company · 10 U.S. investigators

   $273,146research payments

4. Study of Long Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Participants Who Have Completed Study HGT-HIT-094

   Completed · Phase 2, Phase 3 · Hunter Syndrome

   NCT02412787 · Takeda Pharmaceuticals U.S.A., Inc. · 9 U.S. investigators

   $272,987research payments

5. Dose Escalation Study Evaluating Safety of TheraSphere Prostate Cancer (PCa) Device

   Active, not recruiting · Not applicable · Prostate

   NCT06192758 · Boston Scientific Corporation · 2 U.S. investigators

   $271,743research payments

6. A Randomized, Controlled Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System (SUMMIT MAX)

   Completed · Not applicable · Acute Ischemic Stroke

   NCT05018650 · Route 92 Medical, Inc. · 17 U.S. investigators

   $271,422research payments

7. Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)

   Recruiting · Phase 3 · Community-acquired Pneumonia

   NCT05722938 · Biotest AG · 5 U.S. investigators

   $270,218research payments

8. Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment

   Completed · Phase 1 · Tumor, Solid

   NCT05661461 · Aadi Bioscience, Inc. · 2 U.S. investigators

   $270,088research payments

9. A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

   Recruiting · Phase 3 · Alzheimer Disease

   NCT07011732 · E.r. Squibb & Sons, L.l.c. · 19 U.S. investigators

   $269,034research payments

10. POLARx Post Approval Study (POLARx PAS)

    Completed · Not applicable · Paroxysmal Atrial Fibrillation

    NCT06170606 · Boston Scientific Corporation · 10 U.S. investigators

    $266,639research payments

11. A Study of LY4175408 in Participants With Advanced Cancer

    Recruiting · Phase 1 · Carcinoma, Non-Small-Cell Lung

    NCT07046923 · Eli Lilly and Company · 2 U.S. investigators

    $265,857research payments

12. Investigating Medication vs. Prostatic Urethral Lift: Assessment and Comparison of Therapies for BPH

    Status unknown · Phase 4 · BPH

    NCT04987892 · Teleflex LLC · 12 U.S. investigators

    $265,072research payments

13. [Trial of device that is not approved or cleared by the U.S. FDA]

    Withheld

    NCT04189913 · Teleflex LLC · 4 U.S. investigators

    $263,895research payments

14. Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)

    Terminated · Phase 1 · Solid Tumor, Adult

    NCT05840510 · E.r. Squibb & Sons, L.l.c. · 3 U.S. investigators

    $263,509research payments

15. A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors

    Terminated · Phase 1, Phase 2 · Advanced Solid Tumor

    NCT04799054 · Ascendis Pharma Endocrinology Inc · 12 U.S. investigators

    $262,153research payments

16. Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion

    Active, not recruiting · Not applicable · Stroke

    NCT05069558 · Occlutech US LLC · 0 U.S. investigators

    $262,063research payments

17. Magenta Elevate™ EFS in High-Risk PCI Patients

    Completed · Not applicable · High-risk Percutaneous Coronary Intervention

    NCT05727059 · Magenta Medical Inc · 10 U.S. investigators

    $261,791research payments

18. Safety and Efficacy Study of S-309309 in Obese Adults

    Completed · Phase 2 · Obesity

    NCT05925114 · Shionogi Inc · 23 U.S. investigators

    $261,066research payments

19. One Year Trial Evaluating Safety of Ozurdex With Eylea

    Completed · Phase 4 · Diabetic Macular Edema

    NCT03984110 · AbbVie Inc. · 1 U.S. investigator

    $260,700research payments

20. Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)

    Completed · Phase 3 · Immune Thrombocytopenia

    NCT04562766 · Sanofi US Services Inc. · 9 U.S. investigators

    $260,251research payments

21. A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color

    Completed · Phase 3 · Atopic Dermatitis

    NCT05372419 · Eli Lilly and Company · 32 U.S. investigators

    $259,421research payments

22. Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

    Recruiting · Phase 3 · Neovascular Age-related Macular Degeneration

    NCT07007065 · AbbVie Inc. · 21 U.S. investigators

    $258,764research payments

23. Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

    Recruiting · Phase 3 · Crohn's Disease

    NCT06937099 · Eli Lilly and Company · 8 U.S. investigators

    $258,435research payments

24. A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide

    Completed · Phase 2 · Functional Constipation

    NCT05760313 · AbbVie Inc. · 20 U.S. investigators

    $257,222research payments

25. A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid

    Completed · Phase 3 · Asthma

    NCT05292586 · Chiesi USA, Inc. · 24 U.S. investigators

    $256,775research payments

26. A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis

    Completed · Phase 3 · Moderate Chronic Plaque Psoriasis

    NCT04123795 · UCB SA · 10 U.S. investigators

    $256,226research payments

27. A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

    Completed · Phase 3 · Hodgkin Lymphoma

    NCT01712490 · Takeda Pharmaceuticals U.S.A., Inc. · 62 U.S. investigators

    $255,754research payments

28. A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

    Completed · Phase 2 · Myelofibrosis (MF)

    NCT03222609 · AbbVie Inc. · 19 U.S. investigators

    $253,022research payments

29. Global Registry for Endovascular Aortic Treatment (GREAT)

    Active, not recruiting · Multiple Pathologies

    NCT01658787 · W. L. Gore & Associates, Inc. · 46 U.S. investigators

    $252,378research payments

30. Open-Label Study to Evaluate the Safety and Effectiveness of the Spirair Implant

    Active, not recruiting · Not applicable · Nasal Septal Deviation

    NCT06163404 · Spirair, Inc. · 5 U.S. investigators

    $252,157research payments

31. A Study of Participants with Β-Thalassemia Treated with Betibeglogene Autotemcel

    Recruiting · Beta-Thalassemia

    NCT06271512 · Genetix Biotherapeutics Inc · 5 U.S. investigators

    $252,062research payments

32. Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients

    Active, not recruiting · Not applicable · Unresectable Hepatocellular Carcinoma

    NCT04736121 · Sirtex Medical Inc · 12 U.S. investigators

    $251,524research payments

33. A Study of DS-7011a in Patients With Systemic Lupus Erythematosus

    Completed · Phase 1, Phase 2 · Systemic Lupus Erythematosus

    NCT05638802 · Daiichi Sankyo Inc. · 15 U.S. investigators

    $250,615research payments

34. Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study

    Completed · Prurigo Nodularis

    NCT05991323 · Sanofi US Services Inc. · 25 U.S. investigators

    $249,277research payments

35. Comparison of Anticoagulation With Left Atrial Appendage Closure After AF Ablation

    Completed · Not applicable · Atrial Fibrillation

    NCT03795298 · Boston Scientific Corporation · 53 U.S. investigators

    $248,290research payments

36. Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults

    Completed · Phase 1 · Influenza, Human

    NCT05875961 · Seqirus USA Inc · 3 U.S. investigators

    $248,095research payments

37. Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 2)

    Completed · Phase 3 · Relapsing Multiple Sclerosis

    NCT04410991 · Genzyme Corporation · 14 U.S. investigators

    $248,091research payments

38. A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection

    Recruiting · Phase 1 · Hepatitis B Virus Infection

    NCT07024641 · Grifols Shared Services North America, Inc. · 10 U.S. investigators

    $245,283research payments

39. A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis

    Active, not recruiting · Phase 4 · Dermatitis Atopic

    NCT05983068 · Genzyme Corporation · 2 U.S. investigators

    $244,425research payments

40. A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both

    Completed · Phase 3 · Type2 Diabetes

    NCT05260021 · Eli Lilly and Company · 12 U.S. investigators

    $243,173research payments

41. A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence Epilepsy

    Active, not recruiting · Phase 3 · Childhood Absence Epilepsy

    NCT06315322 · UCB SA · 6 U.S. investigators

    $242,900research payments

42. ANG-First Trial (Angiotensin II as First-Line Vasopressor Therapy in Cardiac Surgery)

    Recruiting · Phase 4 · Vasodilatory Hypotension During or After Cardiac Surgery

    NCT06487585 · La Jolla Pharmaceutical Company · 1 U.S. investigator

    $241,944research payments

43. Safety Evaluation of Prismocitrate 18 in Patients Receiving CRRT

    Recruiting · Phase 3 · Regional Citrate Anticoagulation (RCA)

    NCT05399537 · Vantive US Healthcare LLC · 7 U.S. investigators

    $241,646research payments

44. A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)

    Terminated · Phase 3 · Dermatomyositis

    NCT04044690 · Csl Behring · 14 U.S. investigators

    $239,589research payments

45. AXIOS™ Gastroenterostomy for Gastric Outlet Obstruction IDE

    Suspended · Not applicable · Gastric Outlet Obstruction

    NCT06174805 · Boston Scientific Corporation · 5 U.S. investigators

    $238,392research payments

46. PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence

    Recruiting · Phase 2 · Prostate Cancer (Post Prostatectomy)

    NCT06617481 · Blue Earth Diagnostics · 1 U.S. investigator

    $238,093research payments

47. Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation

    Completed · Phase 3 · Chronic Obstructive Pulmonary Disease

    NCT04456673 · Sanofi US Services Inc. · 26 U.S. investigators

    $237,496research payments

48. A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia

    Active, not recruiting · Phase 3 · Hemophilia

    NCT05662319 · Genzyme Corporation · 10 U.S. investigators

    $236,111research payments

49. Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

    Active, not recruiting · Phase 3 · Crohn's Disease (CD)

    NCT04524611 · AbbVie Inc. · 17 U.S. investigators

    $235,945research payments

50. A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment

    Active, not recruiting · Primary Biliary Cholangitis

    NCT06447168 · Ipsen Pharma Sas · 13 U.S. investigators

    $235,544research payments

Sources: CMS Open Payments research payments, program year 2025 (trials with a ClinicalTrials.gov number), and ClinicalTrials.gov (U.S. National Library of Medicine). Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally.